Exploiting the clonal origin of metastatic cancer plus a workaround for the immuno-somnolence of cancer

Clonal tumors develop from a single cancer cell and thus share markers, some of which may be targetable and either highly or even completely conserved.

Cancer puts the immune system into either a somnolent state or a succoring state that is otherwise somnolent.

How can one rouse a person’s immune system against a conserved marker? There are always multiple paths. How about amplifying populations of cells against that marker outside a person’s body and re-injecting the amplified cells?

Here is a leading reference to a workable approach:


Dec. 8, 2016

A woman with metastatic colon cancer is, for now, free of disease after her immune cells were carefully selected to target a gene mutation buried in her tumors, The New York Times reports. As reported today in The New England Journal of Medicine, the 50-year-old engineer and mother of five is the first to benefit from such a therapy, and it’s generating excitement—in part because the mutation, KRAS, is extremely common in certain cancers, has been highly resistant to drugs, and often tracks with a poor prognosis. The woman was treated in a clinical trial at the National Cancer Institute in Bethesda, Maryland, by a team led by Steven Rosenberg, who pioneered use of these immune cells, tumor-infiltrating lymphocytes, against cancer back in the 1990s.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s